PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 86-88

  Karwacz, Katarzyna ^a   Arce, Frederick ^b   Bricogne, Christopher ^c   Kochan, Grazyna ^d   Escors, David ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Paul O'Gorman Building ^*  (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CBL E3 PROTEIN; CBL PROTEIN; CD40 ANTIGEN; CELL PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PD L1 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION;

EID: 84866363876     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.17824     Document Type: Note

References (10)

1. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J 2006; 25:2623-33.
2. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004; 101:10691-6.
3. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34.
4. + T cells. EMBO Mol Med 2011; DOI:10.1002/emmm.201100165.
5. San Jose E, Borroto A, Niedergang F, Alcover A, Alarcon B. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity 2000; 12:161-70.
6. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54:307-14.
7. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010; 184:3442-9.
8. Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, et al. Targeting dendritic cell signalling to regulate the response to immunisation. Blood 2008; 111:3050-61.
9. Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011; 63:84-95.
10. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13.